×

Small fatty molecules may predict future relapse risk in early MS: Study

Among people with clinically isolated syndrome (CIS) — an initial episode of symptoms suggestive of multiple sclerosis (MS) — lower levels of certain fatty molecules in the blood are associated with higher rates of future disease relapses, a new study found. Adding these metabolic features…

How PTSD might manifest for people with a chronic illness like MS

Many people tend to associate post-traumatic stress disorder (PTSD) with military service. While the military may provide ample opportunities for exposure to a traumatic event, it by no means has a monopoly on the disorder. Trauma can be caused by many other situations, including terrifying…

New MPI technology can map where therapeutic cells go in the body

A new study in mice shows that an advanced imaging technique called magnetic particle imaging, or MPI, can track exactly where therapeutic cells go after they are injected into the body. This approach could eventually help researchers and doctors study and optimize cell-based therapies for…

Finding a place for Able Me

I’ve written before about therapy and how important it is to me. Today therapy provided me with context for one of the most daunting situations I’ve found myself in for a very long time. Dr. KB has helped me identify the fact that I am…

The things I miss from life before multiple sclerosis

Because multiple sclerosis (MS) is so unpredictable, many of us experience a silent battle of grieving what was, while simultaneously navigating what will become of our lives. It might seem to an outsider that the sorrow comes from mourning only the loss of major milestones,…

Your Choice?

Tweet Someone just asked me about selection of treatments and choice and as an outsider I thought that you would be given information of what is available to you and there is then some choice….However, I replied I think there is significant medical gaslighting to…

FDA puts clinical hold on planned Phase 2 trial of Lucid-MS

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Quantum Biopharma’s application seeking clearance to begin a Phase 2 trial testing Lucid-MS in people with multiple sclerosis (MS). Quantum said the FDA requested further information before clearing the investigational new drug…